Literature DB >> 18442554

Risk factor analysis for bridge to transplantation with the CardioWest total artificial heart.

Jack G Copeland1, Richard G Smith, Raj K Bose, Pei H Tsau, Paul E Nolan, Marvin J Slepian.   

Abstract

BACKGROUND: Safety and efficacy studies of various mechanical circulatory support devices are important, but may not be strictly comparable. Lacking prospective randomized studies for different devices, we believe that comparison of risk factor analyses may give the surgeon a tool more powerful than current studies for matching a patient with an appropriate device. In this paper, we report risk factor profiles for bridge to transplantation with the CardioWest total artificial heart and summarize reports for other devices.
METHODS: A multiinstitutional risk factor analysis of the CardioWest total artificial heart, as a bridge to transplantation in 81 patients, was conducted. Univariate analyses were performed on 43 preimplantation prognostic factors. From this group, eight factors were chosen for multivariate analysis. Our results were compared with all recent risk factor analyses for other devices.
RESULTS: Independent predictors for death at three intervals by multivariate analysis were as follows: "implant to transplant": history of smoking (odds ratio, 34); "implant to 30 days after transplant": history of smoking (odds ratio, 10.00), prothrombin time greater than 16 seconds (odds ratio, 4.76); and "implant to 1 year after transplant": prothrombin time greater than 16 seconds (odds ratio, 3.85). The major difference between this experience and multiple reported experiences with left ventricular assist devices is that for left ventricular assist devices, but not for the temporary CardioWest total artificial heart, right heart failure, high central venous pressure, and being on a ventilator (with or without sepsis) were independent predictors of mortality.
CONCLUSIONS: Risk factors for bridge to transplantation with the CardioWest total artificial heart are different from those reported for left ventricular assist devices. Recognition of these risk factor differences may facilitate appropriate device selection.

Entities:  

Mesh:

Year:  2008        PMID: 18442554     DOI: 10.1016/j.athoracsur.2008.01.052

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Cardiovascular implantable device infections.

Authors:  George M Viola; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

Review 2.  Mechanical circulatory support.

Authors:  Deborah J Kozik; Mark D Plunkett
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

3.  Out-of-hospital total artificial heart patients: bridge to transplantation.

Authors:  Jack Copeland
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  A ventricular assist device as a bridge to recovery, decision making, or transplantation in patients with advanced cardiac failure.

Authors:  Siyamek Neragi-Miandoab
Journal:  Surg Today       Date:  2012-07-20       Impact factor: 2.549

5.  Progress on the design and development of the continuous-flow total artificial heart.

Authors:  Mariko Kobayashi; David J Horvath; Nicole Mielke; Akira Shiose; Barry Kuban; Mark Goodin; Kiyotaka Fukamachi; Leonard A R Golding
Journal:  Artif Organs       Date:  2012-07-02       Impact factor: 3.094

6.  Implantation of the syncardia total artificial heart.

Authors:  Daniel G Tang; Keyur B Shah; Micheal L Hess; Vigneshwar Kasirajan
Journal:  J Vis Exp       Date:  2014-07-18       Impact factor: 1.355

7.  Experience with the SynCardia total artificial heart in a Canadian centre.

Authors:  Anthony Nguyen; Michel Pellerin; Louis P Perrault; Michel White; Anique Ducharme; Normand Racine; Michel Carrier
Journal:  Can J Surg       Date:  2017-12       Impact factor: 2.089

8.  Past and present of cardiocirculatory assist devices: a comprehensive critical review.

Authors:  Gianluca Rigatelli; Francesco Santini; Giuseppe Faggian
Journal:  J Geriatr Cardiol       Date:  2012-12       Impact factor: 3.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.